CCO Independent Conference Highlights of the 2024 ELCC Annual Congress *

Review summary slidesets, focused commentary, and expert analysis of the most clinically relevant data presented at ELCC 2024.

Share

Program Content

Activities

ELCC 2024 Updates
Key Updates in Lung Cancers From the ELCC 2024 Annual Meeting
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: May 03, 2024

Expires: May 02, 2025

6 Capsule Summary Slidesets

Activities

PACIFIC 2
PACIFIC-2: Final Analysis of Concurrent Durvalumab + CRT Followed by Consolidation Durvalumab for Unresectable Stage III NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 29, 2024

Expires: April 28, 2025

Subcutaneous Amivantamab
PALOMA: Phase Ib Trial of Subcutaneous Amivantamab Given Every 4 Wk in Patients With Advanced Solid Tumors
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 02, 2024

Expires: May 01, 2025

FLAURA2 Postprogression Outcomes
FLAURA2: Postprogression Outcomes of First-line Osimertinib ± Platinum-Based Chemotherapy in EGFR-Mutated Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 03, 2024

Expires: May 02, 2025

DeLLphi-300
DeLLphi-300: Long-term Follow-up From Phase I Study of Tarlatamab, a DLL3-Targeted Bispecific T-Cell Engager, in Previously Treated SCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 13, 2024

Expires: May 12, 2025

EMPOWER-Lung 3 Part 1
EMPOWER-Lung 3 Part 1: Patient-Reported Outcomes With First-line Cemiplimab + Chemotherapy + Ipilimumab in Advanced NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 13, 2024

Expires: May 12, 2025

RATIONALE 315
RATIONALE-315: Surgical Outcomes From Phase III Trial of Perioperative Tislelizumab, a PD-1 Inhibitor, Plus Neoadjuvant Chemotherapy in Resectable NSCLC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: May 16, 2024

Expires: May 15, 2025

Activities

2024 ELCC Highlights
Highlights From the 2024 ELCC Annual Congress
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: June 26, 2024

Expires: December 25, 2024

Faculty

cover img faculity

Luis Paz-Ares, MD, PhD

Chair of the Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor
Universidad Complutense de Madrid
Head of the Lung Cancer Unit
CNIO (Spanish National Cancer Research Center)
Madrid, Spain

cover img faculity

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.